MDSpire - Summary
Feature

AI-Driven Multiagent System for Guiding First-Line Immunotherapy for NSCLC

An artificial intelligence (AI) multiagent system demonstrated correct and complete reasoning in determining the use of immunotherapy for patients with non–small cell lung cancer (NSCLC) in the first-...

Share

An AI multiagent system has shown capability in determining immunotherapy options for patients with non-small cell lung cancer (NSCLC) in a first-line setting. Presented by Dr. Federica Corso at the ESMO AI & Digital Oncology Congress, the system integrates diverse patient data to optimize treatment recommendations. In a study involving 58 stage IV NSCLC patients, the system achieved 72% correctness in treatment suggestions and 91% completeness, demonstrating the potential of agentic AI in clinical decision-making and highlighting the need for further validation.

Original Source(s)

AI-Driven Multiagent System for Guiding First-Line Immunotherapy for NSCLC

  • by Lisa Astor

  • April 1, 2026

Related Content

Early Results From a Trial of Active Surveillance for Low-Risk DCIS are ‘Reassuring,’ Say Researchers

“For women with low-risk DCIS, these interim results are reassuring. There is currently no indication that active surveillance leads to worse early outcomes compared with immediate surgery. It’s impor...

Could Mass Spec Overcome the CAR T Solid Tumor Barrier?

Joey Sheff explains how proteomics is revealing targets, guiding CAR design, and predicting function in solid tumors.

  • April 1, 2026

  • 8 min
From One Stem Cell to Millions of Cancer Killers

A three-step engineering strategy generates vast numbers of potent NK immune cells – potentially slashing the cost and scaling of cancer immunotherapy

  • April 1, 2026

  • 1 min